Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Löwenberg, Bob ; Beck, Joachim ; Graux, Carlos ; van Putten, Wim ; Schouten, Harry C. ; Verdonck, Leo F. ; Ferrant, Augustin ; Sonneveld, Pieter ; Jongen-Lavrencic, Mojca ; von Lilienfeld-Toal, Marie ; Biemond, Bart J. ; Vellenga, Edo ; Breems, Dimitri ; de Muijnck, Hilde ; Schaafsma, Ron ; Verhoef, Gregor ; Döhner, Hartmut ; Gratwohl, Alois ; Pabst, Thomas ; Ossenkoppele, Gert J. ; Maertens, Johan ; for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) ; German Austrian AML Study Group (AMLSG) ; Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)

Blood, 2010-04, Vol.115 (13), p.2586-2591 [Periódico revisado por pares]

Washington, DC: Elsevier Inc

Texto completo disponível